Search research articles
Contact Us
Filters
Showing results (101-110 of 183) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
Georg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
Leukemia & Lymphoma
|
July 29, 2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience
Ahmed Sawas, Helen Ma, John Kuruvilla, et al.
Hematological Oncology
|
October 13, 2006
Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy
David C Hodgson, Melania Pintilie, Leah Gitterman, et al.
Leukemia & Lymphoma
|
February 22, 2025
Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada
Chathuri Abeyakoon, Esther Ting, Sahar Khan, et al.
Leukemia & Lymphoma
|
February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Current Oncology (Toronto, Ont.)
|
April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
Annette E Hay, Nicole Mittmann, Michael Crump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
Rena Buckstein, Robert S Kerbel, Yuval Shaked, et al.
Leukemia & Lymphoma
|
January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Blood Advances
|
January 26, 2026
Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial
Inna Y Gong, John Kuruvilla, Anca Prica, et al.
Biotechnology Annual Review
|
October 12, 2005
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma
Carol Anne Sawka, Frances A Shepherd, Edmee Franssen, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 183) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
Georg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
Leukemia & Lymphoma
|
July 29, 2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience
Ahmed Sawas, Helen Ma, John Kuruvilla, et al.
Hematological Oncology
|
October 13, 2006
Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy
David C Hodgson, Melania Pintilie, Leah Gitterman, et al.
Leukemia & Lymphoma
|
February 22, 2025
Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada
Chathuri Abeyakoon, Esther Ting, Sahar Khan, et al.
Leukemia & Lymphoma
|
February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Current Oncology (Toronto, Ont.)
|
April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
Annette E Hay, Nicole Mittmann, Michael Crump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
Rena Buckstein, Robert S Kerbel, Yuval Shaked, et al.
Leukemia & Lymphoma
|
January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Blood Advances
|
January 26, 2026
Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial
Inna Y Gong, John Kuruvilla, Anca Prica, et al.
Biotechnology Annual Review
|
October 12, 2005
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma
Carol Anne Sawka, Frances A Shepherd, Edmee Franssen, et al.
Page
of 19